Literature DB >> 18541790

There is no Parkinson disease.

William J Weiner1.   

Abstract

The term Parkinson disease defines a specific clinical condition characterized by a typical history and characteristic signs. This review examines the historical evolution of the concept of Parkinson disease and how the misunderstanding of Parkinson disease may be hindering clinical research trials. It is proposed that this syndrome be called Parkinson diseases or parkinsonism type 1 through infinity.

Entities:  

Mesh：

Year:  2008        PMID： 18541790     DOI： 10.1001/archneur.65.6.705

Source DB:  PubMed          Journal:  Arch Neurol        ISSN： 0003-9942


  18 in total

Review 1.  Integrating Patient Concerns into Parkinson's Disease Management.

Authors:  Shen-Yang Lim; Ai Huey Tan; Susan H Fox; Andrew H Evans; Soon Chai Low
Journal:  Curr Neurol Neurosci Rep       Date:  2017-01       Impact factor: 5.081

Review 2.  'Essential tremor' or 'the essential tremors': is this one disease or a family of diseases?

Authors:  Elan D Louis
Journal:  Neuroepidemiology       Date:  2013-12-03       Impact factor: 3.282

Review 3.  Catechol-O-methyltransferase inhibitors in Parkinson's disease.

Authors:  Thomas Müller
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

Review 4.  α-Synuclein in Parkinson's disease: causal or bystander?

Authors:  Peter Riederer; Daniela Berg; Nicolas Casadei; Fubo Cheng; Joseph Classen; Christian Dresel; Wolfgang Jost; Rejko Krüger; Thomas Müller; Heinz Reichmann; Olaf Rieß; Alexander Storch; Sabrina Strobel; Thilo van Eimeren; Hans-Ullrich Völker; Jürgen Winkler; Konstanze F Winklhofer; Ullrich Wüllner; Friederike Zunke; Camelia-Maria Monoranu
Journal:  J Neural Transm (Vienna)       Date:  2019-06-25       Impact factor: 3.575

Review 5.  Therapy of Parkinson's Disease Subtypes.

Authors:  Connie Marras; K Ray Chaudhuri; Nataliya Titova; Tiago A Mestre
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

6.  Parkin and PINK1 parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson's disease.

Authors:  J Eric Ahlskog
Journal:  Parkinsonism Relat Disord       Date:  2009-10-07       Impact factor: 4.891

Review 7.  How does an occupational neurologist assess welders and steelworkers for a manganese-induced movement disorder? An international team's experiences in Guanxi, China, part I.

Authors:  Jonathan S Rutchik; Wei Zheng; Yueming Jiang; Xuean Mo
Journal:  J Occup Environ Med       Date:  2012-11       Impact factor: 2.162

8.  Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers.

Authors:  C Marras; B Schüle; B Schuele; R P Munhoz; E Rogaeva; J W Langston; M Kasten; C Meaney; C Klein; P M Wadia; S-Y Lim; R S-I Chuang; C Zadikof; T Steeves; K M Prakash; R M A de Bie; G Adeli; T Thomsen; K K Johansen; H A Teive; A Asante; W Reginold; A E Lang
Journal:  Neurology       Date:  2011-07-13       Impact factor: 9.910

Review 9.  Perspective: Treatment for Disease Modification in Chronic Neurodegeneration.

Authors:  Thomas Müller; Bernhard Klaus Mueller; Peter Riederer
Journal:  Cells       Date:  2021-04-12       Impact factor: 6.600

10.  Parkinson's Disease Subtypes: Critical Appraisal and Recommendations.

Authors:  Tiago A Mestre; Seyed-Mohammad Fereshtehnejad; Daniela Berg; Nicolaas I Bohnen; Kathy Dujardin; Roberto Erro; Alberto J Espay; Glenda Halliday; Jacobus J van Hilten; Michele T Hu; Beomseok Jeon; Christine Klein; Albert F G Leentjens; Johan Marinus; Brit Mollenhauer; Ronald Postuma; Rajasumi Rajalingam; Mayela Rodríguez-Violante; Tanya Simuni; D James Surmeier; Daniel Weintraub; Michael P McDermott; Michael Lawton; Connie Marras
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.